Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates

References

• Riggs B L, Melton L J, 3rd. Involutional osteoporosis. N Engl J Med 1986; 314: 1676–1686
   PubMed Web of Science ®Google Scholar
• Ott S M. Bone density in adolescents. N Engl J Med 1991; 325: 1646–1647
   PubMedGoogle Scholar
• Wark J D. Osteoporosis: pathogenesis, diagnosis, prevention and management. Baillieres Clin Endocrinol Metab 1993; 7: 151–181
   Google Scholar
• Hui S L, Wiske P S, Norton J A, Johnston C C, Jr. A prospective study of change in bone mass with age in postmenopausal women. J Chronic Dis 1982; 35: 715–725
   PubMedGoogle Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–1259
   PubMed Web of Science ®Google Scholar
• Cooper C. Femoral neck bone density and fracture risk. Osteoporos Int 1996; 6(Suppl 3)24–26
   Google Scholar
• Kim N, Kadono Y, Takami M, Lee J, Lee S H, Okada F, Kim J H, Kobayashi T, Odgren P R, Nakano H, et al. Osteoclast differentiation independent of the TRANCE–RANK–TRAF6 axis. J Exp Med 2005; 202: 589–595
   PubMed Web of Science ®Google Scholar
• Lambert C, Oury C, Dejardin E, Chariot A, Piette J, Malaise M, Merville M P, Franchimont N. Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 2007; 22: 1350–1361
   Google Scholar
• Karst M, Gorny G, Galvin R J, Oursler M J. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-β regulation of osteoclast differentiation. J Cell Physiol 2004; 200: 99–106
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Saatcioglu F, Matsuda T. Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 2002; 143: 2635–2642
   PubMed Web of Science ®Google Scholar
• Hawse J R, Subramaniam M, Ingle J N, Oursler M J, Rajamannan N M, Spelsberg T C. Estrogen–TGFβ cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem 2008; 103: 383–392
   Google Scholar
• Yakar S, Rosen C J, Beamer W G, Ackert-Bicknell C L, Wu Y, Liu J L, Ooi G T, Setser J, Frystyk J, Boisclair Y R, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771–781
   PubMed Web of Science ®Google Scholar
• Weitzmann M N, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005; 208: 154–168
   PubMed Web of Science ®Google Scholar
• Fuller K, Murphy C, Kirstein B, Fox S W, Chambers T J. TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108–1118
   PubMed Web of Science ®Google Scholar
• Nanes M S. Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 2003; 321: 1–15
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker J E, Kanagawa O, Ross F P, Teitelbaum S L. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481–1488
   PubMed Web of Science ®Google Scholar
• Wei S, Kitaura H, Zhou P, Ross F P, Teitelbaum S L. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282–290
   PubMed Web of Science ®Google Scholar
• Abe E, Marians R C, Yu W, Wu X B, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair H C, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151–162
   PubMed Web of Science ®Google Scholar
• Sun L, Peng Y, Sharrow A C, Iqbal J, Zhang Z, Papachristou D J, Zaidi S, Zhu L L, Yaroslavskiy B B, Zhou H, et al. FSH directly regulates bone mass. Cell 2006; 125: 247–260
   PubMed Web of Science ®Google Scholar
• Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies T F, Sun L, Zaidi M, et al. TNFα mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A 2006; 103: 12849–12854
   Google Scholar
• Iqbal J, Sun L, Kumar T R, Blair H C, Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006; 103: 14925–14930
   PubMed Web of Science ®Google Scholar
• Kaneki H, Guo R, Chen D, Yao Z, Schwarz E M, Zhang Y E, Boyce B F, Xing L. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281: 4326–4333
   PubMedGoogle Scholar
• Kousteni S, Bellido T, Plotkin L I, O'Brien C A, Bodenner D L, Han L, Han K, DiGregorio G B, Katzenellenbogen J A, Katzenellenbogen B S, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719–730
   PubMed Web of Science ®Google Scholar
• Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor β in rat bone. Endocrinology 1997; 138: 4509–4512
   PubMed Web of Science ®Google Scholar
• Arts J, Kuiper G G, Janssen J M, Gustafsson J A, Lowik C W, Pols H A, van Leeuwen J P. Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 1997; 138: 5067–5070
   PubMed Web of Science ®Google Scholar
• Smith E P, Boyd J, Frank G R, Takahashi H, Cohen R M, Specker B, Williams T C, Lubahn D B, Korach K S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–1061
   PubMed Web of Science ®Google Scholar
• Kousteni S, Han L, Chen J R, Almeida M, Plotkin L I, Bellido T, Manolagas S C. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003; 111: 1651–1664
   PubMed Web of Science ®Google Scholar
• Hofbauer L C, Lacey D L, Dunstan C R, Spelsberg T C, Riggs B L, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25: 255–259
   PubMed Web of Science ®Google Scholar
• Cenci S, Weitzmann M N, Roggia C, Namba N, Novack D, Woodring J, Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Invest 2000; 106: 1229–1237
   PubMed Web of Science ®Google Scholar
• Roggia C, Gao Y, Cenci S, Weitzmann M N, Toraldo G, Isaia G, Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001; 98: 13960–13965
   PubMed Web of Science ®Google Scholar
• Stein B, Yang M X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBP β. Mol Cell Biol 1995; 15: 4971–4979
   PubMed Web of Science ®Google Scholar
• Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site. Nucleic Acids Res 1997; 25: 2424–2429
   PubMed Web of Science ®Google Scholar
• Hughes D E, Dai A, Tiffee J C, Li H H, Mundy G R, Boyce B F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 1996; 2: 1132–1136
   PubMed Web of Science ®Google Scholar
• Reid I R, Eastell R, Fogelman I, Adachi J D, Rosen A, Netelenbos C, Watts N B, Seeman E, Ciaccia A V, Draper M W. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164: 871–879
   PubMed Web of Science ®Google Scholar
• Bord S, Ireland D C, Beavan S R, Compston J E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32: 136–141
   PubMed Web of Science ®Google Scholar
• Liao E Y, Luo X H, Su X. Comparison of the effects of 17β-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 2002; 25: 785–790
   Google Scholar
• Chen C, Noland K A, Kalu D N. Modulation of intestinal vitamin D receptor by ovariectomy, estrogen and growth hormone. Mech Ageing Dev 1997; 99: 109–122
   PubMed Web of Science ®Google Scholar
• Tiegs R D, Body J J, Wahner H W, Barta J, Riggs B L, Heath H, 3rd. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med 1985; 312: 1097–1100
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–944
   PubMed Web of Science ®Google Scholar
• Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986; 38: 342–349
   PubMed Web of Science ®Google Scholar
• Lehenkari P P, Kellinsalmi M, Napankangas J P, Ylitalo K V, Monkkonen J, Rogers M J, Azhayev A, Vaananen H K, Hassinen I E. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61: 1255–1262
   PubMed Web of Science ®Google Scholar
• Goldstein J L, Brown M S. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430
   PubMed Web of Science ®Google Scholar
• Roskoski R, Jr. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 2003; 303: 1–7
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990; 5: 31–40
   PubMed Web of Science ®Google Scholar
• Razzouk S, Lieberherr M, Cournot G. Rac-GTPase, osteoclast cytoskeleton and bone resorption. Eur J Cell Biol 1999; 78: 249–255
   PubMedGoogle Scholar
• Christensen M S, Hagen C, Christiansen C, Transbol I. Dose–response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982; 144: 873–879
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen M S, Larsen N E, Transbol I B. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose–response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982; 55: 1124–1130
   PubMed Web of Science ®Google Scholar
• Munk-Jensen N, Pors Nielsen S, Obel E B, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br Med J (Clin Res Ed) 1988; 296: 1150–1152
   PubMed Web of Science ®Google Scholar
• Christiansen C, Riis B J. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 1990; 97: 1087–1092
   PubMedGoogle Scholar
• Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinol (Copenh) 1990; 123: 14–18
   PubMedGoogle Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, Bassford T, Beresford S A, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Vedi S, Purdie D W, Ballard P, Bord S, Cooper A C, Compston J E. Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos Int 1999; 10: 52–58
   PubMed Web of Science ®Google Scholar
• Hosking D, Chilvers C E, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998; 338: 485–492
   PubMed Web of Science ®Google Scholar
• Harris S T, Watts N B, Genant H K, McKeever C D, Hangartner T, Keller M, Chesnut C H, 3rd, Brown J, Eriksen E F, Hoseyni M S, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–1352
   PubMed Web of Science ®Google Scholar
• Hosking D, Adami S, Felsenberg D, Andia J C, Valimaki M, Benhamou L, Reginster J Y, Yacik C, Rybak-Feglin A, Petruschke R A, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003; 19: 383–394
   PubMed Web of Science ®Google Scholar
• Hooper M J, Ebeling P R, Roberts A P, Graham J J, Nicholson G C, D'Emden M, Ernst T F, Wenderoth D. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric 2005; 8: 251–262
   PubMed Web of Science ®Google Scholar
• Wasnich R D, Bagger Y Z, Hosking D J, McClung M R, Wu M, Mantz A M, Yates J J, Ross P D, Alexandersen P, Ravn P, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004; 11: 622–630
   PubMedGoogle Scholar
• Ensrud K E, Barrett-Connor E L, Schwartz A, Santora A C, Bauer D C, Suryawanshi S, Feldstein A, Haskell W L, Hochberg M C, Torner J C, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19: 1259–1269
   PubMed Web of Science ®Google Scholar
• Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30–34
   PubMed Web of Science ®Google Scholar
• Vaisman D N, McCarthy A D, Cortizo A M. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res 2005; 104: 131–140
   Google Scholar
• Ravn P, Bidstrup M, Wasnich R D, Davis J W, McClung M R, Balske A, Coupland C, Sahota O, Kaur A, Daley M, et al. Alendronate and estrogen–progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131: 935–942
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999; 24: 237–244
   Google Scholar
• Ravn P, Hosking D, Thompson D, Cizza G, Wasnich R D, McClung M, Yates A J, Bjarnason N H, Christiansen C. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999; 84: 2363–2368
   PubMed Web of Science ®Google Scholar
• Odvina C V, Zerwekh J E, Rao D S, Maalouf N, Gottschalk F A, Pak C Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294–1301
   PubMed Web of Science ®Google Scholar
• Finkelstein J S, Hayes A, Hunzelman J L, Wyland J J, Lee H, Neer R M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216–1226
   PubMed Web of Science ®Google Scholar
• Black D M, Greenspan S L, Ensrud K E, Palermo L, McGowan J A, Lang T F, Garnero P, Bouxsein M L, Bilezikian J P, Rosen C J. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207–1215
   PubMed Web of Science ®Google Scholar
• Fleurence R, Torgerson D J, Reid D M. Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporos Int 2002; 13: 637–643
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Lobo R A, Walsh B W, Harris S T, Reagan J E, Liss C L, Melton M E, Byrnes C A. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84: 3076–3081
   PubMed Web of Science ®Google Scholar
• Harris S T, Eriksen E F, Davidson M, Ettinger M P, Moffett A H, Jr, Baylink D J, Crusan C E, Chines A A. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1890–1897
   PubMed Web of Science ®Google Scholar
• Evio S, Tiitinen A, Laitinen K, Ylikorkala O, Valimaki M J. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004; 89: 626–631
   PubMed Web of Science ®Google Scholar
• Scimeca J C, Franchi A, Trojani C, Parrinello H, Grosgeorge J, Robert C, Jaillon O, Poirier C, Gaudray P, Carle G F. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26: 207–213
   PubMed Web of Science ®Google Scholar
• Quarello P, Forni M, Barberis L, Defilippi C, Campagnoli M F, Silvestro L, Frattini A, Chalhoub N, Vacher J, Ramenghi U. Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 2004; 19: 1194–1199
   PubMedGoogle Scholar
• Kong Y Y, Yoshida H, Sarosi I, Tan H L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos A J, Van G, Itie A, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315–323
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Yan X Q, Morony S, Capparelli C, Tan H L, McCabe S, Elliott R, Scully S, Van G, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97: 1566–1571
   PubMed Web of Science ®Google Scholar
• Kornak U, Kasper D, Bosl M R, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch T J. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104: 205–215
   PubMed Web of Science ®Google Scholar
• Bathi R J, Masur V N. Pyknodysostosis – a report of two cases with a brief review of the literature. Int J Oral Maxillofac Surg 2000; 29: 439–442
   Google Scholar
• Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M T, Martin T J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345–357
   PubMed Web of Science ®Google Scholar
• Mashiba T, Hirano T, Turner C H, Forwood M R, Johnston C C, Burr D B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 613–620
   PubMed Web of Science ®Google Scholar
• Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28: 524–531
   PubMed Web of Science ®Google Scholar
• Burr D B, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston C C. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003; 33: 960–969
   Google Scholar
• Mashiba T, Mori S, Burr D B, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23(Suppl)36–42
   PubMed Web of Science ®Google Scholar
• Li J, Sato M, Jerome C, Turner C H, Fan Z, Burr D B. Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 2005; 23(Suppl)48–54
   Google Scholar
• Karsdal M A, Qvist P, Christiansen C, Tanko L B. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression. Drugs 2006; 66: 1909–1918
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart J M, Castronovo V, Green J R. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055–1061
   PubMed Web of Science ®Google Scholar
• Hellstein J W, Marek C L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century. J Oral Maxillofac Surg 2005; 63: 682–689
   PubMed Web of Science ®Google Scholar
• Migliorati C A, Schubert M M, Peterson D E, Seneda L M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83–93
   PubMed Web of Science ®Google Scholar
• Purcell P M, Boyd I W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005; 182: 417–418
   PubMed Web of Science ®Google Scholar
• Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini Prato G. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123–1128
   PubMed Web of Science ®Google Scholar
• Vannucchi A M, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005; 128: 738
   PubMedGoogle Scholar
• Robinson N A, Yeo J F. Bisphosphonates – a word of caution. Ann Acad Med Singapore 2004; 33(4 Suppl)48–49
   Google Scholar
• Ruggiero S L, Mehrotra B, Rosenberg T J, Engroff S L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527–534
   PubMed Web of Science ®Google Scholar
• Thomsen J S, Ebbesen E N, Mosekilde L. Predicting human vertebral bone strength by vertebral static histomorphometry. Bone 2002; 30: 502–508
   PubMed Web of Science ®Google Scholar
• Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Fox S, Chow J. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 2001; 86: 289–295
   PubMed Web of Science ®Google Scholar
• Stepan J J, Burr D B, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007; 41: 378–385
   PubMed Web of Science ®Google Scholar
• Roughead E E, McGeechan K, Sayer G P. Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 2004; 57: 813–816
   Google Scholar
• Barrera B A, Wilton L, Harris S, Shakir S A. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int 2005; 16: 1989–1998
   Google Scholar
• Yang Y X, Lewis J D, Epstein S, Metz D C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947–2953
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Prentice R L, Manson J E, Wu L, Barad D, Barnabei V M, Ko M, LaCroix A Z, Margolis K L, Stefanick M L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, Kuller L, Johnson K C, Hendrix S L, Pettinger M, Heckbert S R, Greep N, Crawford S, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Stefanick M L, Anderson G L, Margolis K L, Hendrix S L, Rodabough R J, Paskett E D, Lane D S, Hubbell F A, Assaf A R, Sarto G E, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111
   PubMed Web of Science ®Google Scholar
• Smith D C, Prentice R, Thompson D J, Herrmann W L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164–1167
   PubMed Web of Science ®Google Scholar
• Woodruff J D, Pickar J H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170: 1213–1223
   PubMed Web of Science ®Google Scholar
• Sturdee D W, Wade-Evans T, Paterson M E, Thom M, Studd J W. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. Br Med J 1978; 1: 1575–1577
   PubMed Web of Science ®Google Scholar
• Padwick M L, Pryse-Davies J, Whitehead M I. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. N Engl J Med 1986; 315: 930–934
   PubMed Web of Science ®Google Scholar
• Steiner A Z, Xiang M, Mack W J, Shoupe D, Felix J C, Lobo R A, Hodis H N. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. Obstet Gynecol 2007; 109: 581–587
   Google Scholar
• Weiderpass E, Adami H O, Baron J A, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–1137
   PubMed Web of Science ®Google Scholar
• Marcil M, Brooks-Wilson A, Clee S M, Roomp K, Zhang L H, Yu L, Collins J A, van Dam M, Molhuizen H O, Loubster O, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354: 1341–1346
   PubMed Web of Science ®Google Scholar
• Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette J C, Deleuze J F, Brewer H B, Duverger N, Denefle P, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352–355
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327
   PubMed Web of Science ®Google Scholar
• Thomas D B, Ray R M. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1996; 144: 281–289
   PubMedGoogle Scholar
• Hellberg D, Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res 2005; 25: 3041–3046
   PubMedGoogle Scholar
• Hellberg D, Lindstrom A K, Stendahl U. Correlation between serum estradiol/progesterone ratio and survival length in invasive squamous cell cervical cancer. Anticancer Res 2005; 25: 611–616
   Google Scholar
• Pater A, Bayatpour M, Pater M M. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 1990; 162: 1099–1103
   PubMed Web of Science ®Google Scholar
• Brinton L A. Oral contraceptives and cervical neoplasia. Contraception 1991; 43: 581–595
   PubMed Web of Science ®Google Scholar
• Martin H L, Jr., Nyange P M, Richardson B A, Lavreys L, Mandaliya K, Jackson D J, Ndinya-Achola J O, Kreiss J. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178: 1053–1059
   PubMed Web of Science ®Google Scholar
• Clark J H. A critique of Women's Health Initiative studies (2002–2006). Nucl Recept Signal 2006; 4: e023
   PubMedGoogle Scholar